Zacks Research Expects Reduced Earnings for Globus Medical

Globus Medical, Inc. (NYSE:GMED) – Zacks Research cut their Q4 2027 earnings per share (EPS) estimates for shares of Globus Medical in a report issued on Thursday, October 29th. Zacks Research analyst Team now expects that the medical device company will post earnings per share of $1.35 for the quarter, down from their previous estimate of $1.37. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $4.99 per share.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, August 6th. The medical device company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.24. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The business had revenue of $789.61 million during the quarter, compared to analyst estimates of $782.88 million. During the same quarter last year, the company earned $0.86 EPS. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS.

GMED has been the topic of a number of other research reports. Stifel Nicolaus lowered their target price on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a research note on Wednesday, July 8th. Truist Financial lowered their price objective on Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Thursday, July 16th. Royal Bank Of Canada dropped their price objective on Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a research note on Thursday, October 1st. Wells Fargo & Company lowered their price target on Globus Medical from $103.00 to $99.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. Finally, BTIG Research restated a “neutral” rating on shares of Globus Medical in a research note on Friday, September 18th. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $99.46.

Globus Medical Stock Up 1.9%

NYSE GMED opened at $79.53 on Monday. Globus Medical has a 52 week low of $59.51 and a 52 week high of $101.40. The firm has a market capitalization of $10.68 billion, a P/E ratio of 16.52, a PEG ratio of 1.31 and a beta of 0.96. The company has a 50-day moving average price of $77.49 and a 200-day moving average price of $83.45.

Insider Transactions at Globus Medical

In other Globus Medical news, Director James Tobin sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the transaction, the director owned 15,000 shares in the company, valued at $1,118,700. This trade represents a 66.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Stephen T. Zarrilli sold 25,000 shares of Globus Medical stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total value of $2,176,000.00. Following the completion of the sale, the director directly owned 25,000 shares in the company, valued at approximately $2,176,000. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 18.38% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Paradigm Capital Management Inc. NY bought a new position in shares of Globus Medical during the second quarter valued at approximately $70,042,000. American Capital Management Inc. purchased a new stake in shares of Globus Medical in the second quarter worth approximately $51,599,000. Hawk Ridge Capital Management LP bought a new stake in shares of Globus Medical during the 1st quarter worth approximately $43,078,000. Arrowstreet Capital Limited Partnership lifted its stake in shares of Globus Medical by 107.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 912,905 shares of the medical device company’s stock worth $78,656,000 after acquiring an additional 471,875 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its stake in shares of Globus Medical by 4.5% during the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after acquiring an additional 328,217 shares during the last quarter. 95.16% of the stock is currently owned by institutional investors.

About Globus Medical

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.